IngredientsGenistein (C15H10O5) is a plant-derived, aglycone isoflavone. Its IUPAC chemical name is 5,7-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one, and it is also systematically identified as 4′,5,7-trihydroxyisoflavone or 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one, the hydrolyzed aglycone form of the isoflavonoid glycoside genistin.
Genistein was first isolated in 1899 from the dyer's broom, Genista tinctoria; hence the chemical name. The compound's structure was established in 1926, when it was found to be identical with that of prunetol. It was chemically synthesized in 1928.
Because soy isoflavones have a similar chemical structure to 17-β-estradiol, the potential for genistein as an estrogenic (hormone-like) signaling molecule that binds to estrogen receptors within cells, mimicking the action of estrogen, has been the subject of extensive research.
Genistein is an isoflavone widely distributed in the Fabaceae (legume) family. Isoflavones such as genistein occur in soybeans (Glycine max) and various other plants, including lupin, fava beans, kudzu, psoralea, Flemingia vestita, and coffee. Soybeans are by far the most concentrated source of isoflavones in the human diet.
Genistein, daidzein, and glycitein (and their different chemical forms) comprise approximately 50%, 40%, and 10%, respectively, of the total isoflavone content of soybeans, although there is considerable variation in this ratio among soybean varieties and foods produced from soybeans. In soybeans and unfermented soy foods, isoflavones occur almost entirely as glycosides; the weight of the non-isoflavone part of glycosides (the sugar molecule) accounts for approximately 40% of total weight, so a conversion factor of 0.6 is typically used to convert glycoside into aglycone values.
Isoflavones are contained in soybeans and soy foods in two chemical forms: aglycones (unconjugated form) and glucosides (bound to a sugar molecule). Genistein is also known to occur naturally as a 4′-glucoside (sophoricoside), and a 4′-methyl ether (biochanin A). The primary glycoside form found in soy is genistin (genistein-7-O-glucoside), which must be cleaved to yield the biologically active aglycone genistein.
Genistein is commercially available and may be obtained in synthetic, purified form; synthetic genistein is available, for example, as BONISTEIN from DSM Nutritional Products. Traditional Asian foods made from soybeans include tofu, tempeh, miso, and natto, all of which are significant dietary vehicles for genistein and related isoflavones. There are approximately 3–4 mg isoflavones per gram of protein in traditional Asian soy foods such as tofu, soymilk made from whole soybeans, and edamame; thus, one serving, such as 1 cup soymilk or 3–4 oz tofu, provides approximately 25 mg isoflavones.
The main problem is the great variability in isoflavone content among soy-based foods, not only between different brands but also between different lots of the same brand. Furthermore, the introduction of different soy or purified isoflavone-based nutraceuticals has further magnified this problem. The use of standardized extracts, as well as more controlled and consistent labeling, is therefore advisable.
Genistein as an isolated chemical entity was not identified until the late nineteenth century, and soy-derived isoflavones were not characterized until well into the twentieth century. The history of traditional use therefore refers not to genistein per se, but to the soy foods and other leguminous preparations from which it is obtained.
Average dietary isoflavone intakes in Japan, China, and other Asian countries range from 25 to 50 mg/day, reflecting a long culinary history of soy food consumption stretching back approximately three thousand years in China. Dietary isoflavone intakes are considerably lower in Western countries; 24-hour dietary recall data collected from 36,037 individuals in 10 countries participating in the EPIC study showed average isoflavone intakes to be lower than 1 mg/day.
The root-tuber peel extract of Flemingia vestita is a traditional medicine anthelmintic of the Khasi tribes of India; in research, genistein was found to be the major isoflavone responsible for this deworming property and was subsequently demonstrated to be effective against intestinal parasites such as the poultry cestode Raillietina echinobothrida, the pork trematode Fasciolopsis buski, and the sheep liver fluke Fasciola hepatica.
Due to the estrogenic activity of isoflavones, they are now used as an alternative to traditional hormone replacement therapy (HRT) for treating estrogen-deficient women in menopause or postmenopause. This modern pharmacological application is distinct from traditional dietary use, although it builds on epidemiological observations of lower rates of menopausal symptoms and certain chronic diseases in populations with high soy food consumption.
Genistein can bind to estrogen receptors (ER), ERα and ERβ, but has a stronger affinity for ERβ. ERα activation is mainly implicated in cellular growth and proliferation, while ERβ activation correlates with cellular differentiation and cell fate. At the molecular level, genistein acts as a protein tyrosine kinase (PTK) inhibitor at high concentrations. At lower, nutritionally relevant concentrations, it acts via estrogen receptor-mediated mechanisms.
Acting as a natural selective ER modulator, genistein exerts its estrogen agonist or antagonist action in a tissue- and dose-dependent manner. The promising safety profile of genistein aglycone may be a direct consequence of its greater affinity for ERβ, which is particularly abundant in trabecular bone during the mineralization phase and in artery endothelial tissue, compared to ERα, which is more represented in the reproductive tissues.
Genistein is a strong inhibitor of protein tyrosine kinases. In vitro, genistein is also an agonist of the G protein-coupled estrogen receptor, and binds to and activates all three peroxisome proliferator-activated receptor isoforms, α, δ, and γ. Genistein is a tyrosine kinase inhibitor, mostly of epidermal growth factor receptors. Suggested mechanisms of phytoestrogen action include binding to estrogen receptors, interaction with steroidogenic enzymes (5α-reductase, aromatase, 17β-hydroxysteroid dehydrogenase), and the inhibition of protein kinases (tyrosine protein kinases, protein kinase C).
There is a growing body of experimental evidence showing that the inhibition of human cancer cell growth by genistein is mediated via modulation of genes related to the control of cell cycle and apoptosis. Genistein inhibits the activation of NF-κB and Akt signaling pathways, both of which maintain a homeostatic balance between cell survival and apoptosis. Moreover, genistein antagonizes estrogen- and androgen-mediated signaling pathways in the processes of carcinogenesis. Genistein has also been found to have antioxidant properties and is a potent inhibitor of angiogenesis and metastasis.
In addition to directly binding to the estrogen receptor, receptor tyrosine kinase, and topoisomerase, genistein also modulates a number of key intracellular molecules, such as NF-κB and MAPK, to induce growth arrest and apoptosis. Several in vitro and in vivo studies show that genistein aglycone has antineoplastic effects which stem from multiple actions: (a) modulation of cell growth and proliferation throughout tyrosine kinase and topoisomerase II inhibition, (b) stimulation of the immune system, (c) antiangiogenic effects, and (d) potent antioxidant capacity. Additionally, the anticancer property of genistein may be due to DNA methylation and/or chromatin modification.
Several biological effects of genistein have been reported in preclinical studies, including antioxidant, anti-inflammatory, antibacterial, and antiviral activities, effects on angiogenesis and estrogen signaling, and pharmacological activities on diabetes and lipid metabolism.
Investigations into mechanisms of anti-cancer activity have revealed many pathways including regulation of Hedgehog-Gli1 signaling, modulation of epigenetic activities, seizure of cell cycle and Akt and MEK signaling pathways, among others via which cancer cell proliferation can be controlled.
More than 30 clinical trials of genistein with various disease indications have been conducted to evaluate its clinical efficacy. Based on many animal and human pharmacokinetic studies, it is well known that the most challenging issue for developing genistein as a chemopreventive agent is its low oral bioavailability, which may be the major reason relating to its ambiguous therapeutic effects and large interindividual variations in clinical trials.
The bioavailability of isoflavones requires the conversion of glycosides into biologically active aglycones through the action of small intestinal bacteria (Lactobacillus, Bifidobacterium) β-glucosidases. Subsequently, these aglycones are absorbed into the peripheral circulation. The coupling of metabolic enzymes and efflux transporters plays an important role in genistein distribution and elimination, enabling enteric and enterohepatic recycling and significantly decreasing exposure levels of genistein while prolonging its residence time in vivo.
The endocrine effects of genistein are also attributable to its main metabolite, the (−)-(S)-equol, a potent phytoestrogen generated by intestinal microbiota metabolism. Genistein is metabolized to p-ethylphenol and 4-hydroxyphenyl-2-propionic acid by colonic bacteria, while further reduction of related isoflavones can yield equol. The isoflavone glycoside genistin is converted into genistein by Lactobacillus spp., Bacteroides spp., and Bifidobacterium spp.
Fermentation, use of micromicelles, and modification of its chemical structure have been reported to enhance the bioavailability of genistein. Bacillus subtilis (BSNK-5) fermentation significantly increased the amount of functional components such as genistein in soymilk; similar results were observed for soybean products prepared by other microorganisms (Lactobacillus casei and Lactobacillus fermentum), with the concentration of genistein in the fermented product reaching 2.65 mg/100 mL.
Supplementation with isoflavones appeared to be about 40% less efficient than hormone-replacement therapy in attenuating menopausal hot flashes and required more time to reach its maximum effect. Yet, supplements containing primarily the isoflavone genistein have demonstrated consistent alleviation of menopausal hot flashes.
A cross-over, placebo-controlled study evaluated the effect of 90 mg of daily genistein on markers of bone turnover and menopausal symptoms, involving 100 postmenopausal women who were randomly assigned to daily genistein or placebo for 6 weeks, then crossed over to the alternative for the following 6 weeks. Pure genistein was processed and encapsulated in accordance with British Pharmacopoeia standards; each capsule contained 90 mg of pure genistein. In women with significant hot flushes, genistein reduced symptoms by 30% compared to baseline, and the difference compared to placebo was statistically significant. No effect was observed on biochemical markers of bone turnover, possibly due to the short duration of each arm of the study.
Another randomized controlled study (n = 84) observed that women who were administered genistein for 12 weeks experienced a statistically significant 51% reduction in the number of hot flashes compared to a 30% reduction in the placebo group.
At present, supplements containing sufficient amounts of genistein may help alleviate vasomotor symptoms in women transitioning through menopause. The overall evidence is moderately consistent for genistein-rich preparations, though pooled analyses of current data are hindered by the heterogeneity in soy/soy isoflavone preparations and dosage regimens in short-term interventions (mostly ≤6 months) in small sample-size trials.
A total of 63 randomized controlled trials involving 6,427 postmenopausal women used for meta-analysis revealed the effects of isoflavone intervention on bone mineral density, suggesting benefits in the prevention and treatment of menopause-related osteoporosis.
Specifically, administration of 54 mg/day genistein aglycone to postmenopausal women with low bone mass has resulted in positive (beneficial) changes in vasomotor symptoms, bone mineral density and markers of bone turnover, and some predictors of cardiovascular risk, without harmful estrogenic activity in the breast and uterus.
After 6 to 12 months of daily genistein (54 mg/day) administration, there was a significant decrease in excretion of bone turnover markers.
In a 6-month double-blind pilot study, 70 subjects were randomized to receive daily either calcium only or a geniVida™ bone blend consisting of genistein (30 mg/day), vitamin D3 (800 IU/day), vitamin K1 (150 μg/day), and polyunsaturated fatty acids. Subjects supplemented with the bone blend maintained femoral neck BMD, whereas in the placebo group, BMD significantly decreased (p = 0.007).
However, the more than 25 clinical trials that have examined the effects of isoflavones on bone mineral density have produced mixed results, although two out of three recently published meta-analyses found that soy isoflavones reduced bone loss at the lumbar spine. Only four studies were more than one year in duration. In the study by Marini et al., there were dramatic increases in postmenopausal spinal and hip BMD after genistein supplementation, whereas in the other three longer-term studies, there was little evidence that soy isoflavones produced skeletal benefits.
Overall, evidence for genistein's effect on BMD is mixed. To date, randomized controlled trials examining the effect of soy isoflavones on bone mineral density in postmenopausal women have produced mixed results. Potential benefits of soy isoflavones as an alternative to bone-sparing treatments in women undergoing menopause remain to be determined.
A meta-analysis of randomized controlled trials revealed that genistein significantly reduced the levels of total and low-density lipoprotein (LDL)-cholesterols and systolic blood pressure, supporting its cardioprotective effects.
In a placebo-controlled clinical study, genistein treatment significantly decreased fasting glucose (genistein = −8.7 ± 2.3%; placebo = 3.2 ± 2.3%; P < 0.001), fasting insulin (genistein = −12 ± 3.33%; placebo = 36 ± 3.29%; P < 0.001), and HOMA-IR (genistein = −14 ± 5.8%; placebo = 42 ± 0.6%; P < 0.001) compared to placebo. After genistein treatment, fibrinogen also decreased significantly compared to placebo. The study suggests that genistein may have a favorable effect on some cardiovascular markers.
Genistein shows a protective effect against cardiovascular diseases by improving lipid profiles, weight changes, and reducing LDL cholesterol, and displays benefits in increasing bone mineral density without displaying the side effects commonly associated with estrogen replacement.
A meta-analysis (n = 476) of postmenopausal women with metabolic syndrome demonstrated that women administered genistein supplementation displayed significantly reduced homocysteine, LDL-cholesterol, total cholesterol, and triglycerides and significantly increased HDL-cholesterol.
Current evidence suggests that whole soy components other than isoflavones may have favorable effects on serum lipid profiles. Yet, two recent meta-analyses of randomized controlled trials indicated that isoflavones might exert cardiovascular benefits by improving vascular function in postmenopausal women. The overall signal from the cardiovascular literature is cautiously favorable, but effect sizes are modest and findings are not uniform across all populations or endpoints.
A meta-analysis of 16 prospective cohort studies involving 11,169 breast cancer cases and 648,913 participants reported that women with a high intake of soy foods had a significant reduction of breast cancer risk.
Investigations into mechanisms of anti-cancer activity have revealed many pathways including suppression of tyrosine kinases, regulation of Hedgehog-Gli1 signaling, modulation of epigenetic activities, and seizure of cell cycle and Akt and MEK signaling pathways, through which cancer cell proliferation can be controlled. The observed activities are time- and dose-dependent. In addition, genistein has shown varying results in women depending on physiological parameters such as early or post-menopausal state.
In a clinical experiment, genistein or a placebo was administered for one month to 140 women with early-stage breast cancer. This led to an overexpression of genes controlling the cell cycle, including the EGFR2 receptor and tyrosine kinase.
Despite its low bioavailability limiting its clinical application, genistein shows potential for breast cancer prevention and treatment. However, the overall clinical evidence remains preliminary; most of the mechanistic work is from in vitro and animal studies, and large-scale definitive clinical trials are lacking.
Genistein has been proven to inhibit the migration of prostate cancer cells at physiological concentrations. Despite a good safety profile for supplemental soy isoflavones and soy proteins in prostate cancer patients, larger randomized controlled trials with longer periods of intervention are required to assess whether soy isoflavones could influence the development and/or progression of prostate cancer.
Postmenopausal women with type 2 diabetes (n = 54) who received genistein supplementation experienced significantly reduced fasting blood glucose, glycated hemoglobin, serum triglycerides, and malondialdehyde (MDA), and increased antioxidant status compared to the placebo group.
Clinical trials (mostly in postmenopausal women) have shown that genistein treatment results in improved cholesterol, insulin/glucose, HOMA-IR, and homocysteine levels. This evidence is primarily limited to postmenopausal women and short-duration RCTs; generalizability to broader populations requires further research.
In the GENIAL clinical trial, a double-blind, placebo-controlled, bicentric study, the effect of daily oral supplementation with 120 mg of genistein for 12 months was evaluated in 24 prodromal Alzheimer's disease patients. Genistein treatment resulted in a significant improvement in two of the neurocognitive tests used. The amyloid-beta deposition analysis showed that genistein-treated patients did not increase their uptake in the anterior cingulate gyrus after treatment (p = 0.878), while placebo-treated patients did increase it (p = 0.036). This study shows that genistein may have a role in therapeutics to delay the onset of Alzheimer's dementia in patients with prodromal Alzheimer's disease.
Genistein has been shown to improve cognitive function and reduce beta-amyloid deposition in patients with prodromal Alzheimer's disease. However, small sample sizes and variability in dosages limit the generalizability of these findings. Future trials with larger cohorts and standardized protocols are needed to validate these results.
Regarding skin health, genistein appears to enhance photoprotection, wound healing, elasticity, and hydration, inhibit skin cancer, and reduce wrinkles. This evidence is primarily from in vitro, animal, and small-scale human studies; large, well-controlled clinical trials are lacking.
In at least one clinical study, pure genistein was processed and encapsulated in accordance with British Pharmacopoeia standards, with each capsule containing 90 mg of pure genistein.
A dose of 54 mg/day genistein aglycone administered to postmenopausal women with low bone mass has been used in multiple well-designed studies, resulting in positive changes in vasomotor symptoms, bone mineral density, markers of bone turnover, and cardiovascular risk predictors.
In one pilot study using a combination bone blend, genistein was administered at 30 mg/day alongside vitamin D3, vitamin K1, and polyunsaturated fatty acids for 6 months.
In the GENIAL clinical trial on prodromal Alzheimer's disease, 120 mg of genistein daily was administered orally for 12 months.
Average dietary isoflavone intakes in Japan, China, and other Asian countries range from 25 to 50 mg/day. In Western countries, 24-hour dietary recall data showed average isoflavone intakes to be lower than 1 mg/day in much of Europe.
There are approximately 3–4 mg isoflavones per gram of protein in traditional Asian soy foods such as tofu, soymilk, and edamame; one serving, such as 1 cup soymilk or 3–4 oz tofu, provides approximately 25 mg isoflavones.
Although soy products are generally recognized as safe (GRAS), a GRAS determination specifically for genistein has not been reported. Certain limitations and side effects, such as low bioavailability, biological estrogenic activity, and detrimental effects on thyroid function, have restricted its clinical applications to some extent.
Achievable concentrations of genistein in humans are low, and the use of soybean as a functional food is not devoid of concerns, which are related to genistein's potential side effects resulting from its estrogenic and goitrogenic effects.
In vitro and in vivo studies showed that genistein is a potent inhibitor of thyroid peroxidase (TPO), a key enzyme in thyroid hormone synthesis. TPO catalyzes the iodination of thyroglobulin and oxidative coupling of diiodothyronine resulting in thyroid hormone formation. Thus, inhibition of TPO leads to a reduction of thyroid hormone levels, with a subsequent increment of TSH release, which in turn provides a strong growth stimulus to the thyroid gland. Moreover, genistein also affects the metabolism of thyroid hormones and iodide re-utilization by inhibition of sulfotransferase enzymes.
Both genistein and daidzein can act as competitive substrates for thyroid peroxidase; genistein (and with lower potency daidzein) inhibits binding of transthyretin to thyroxin (T4) and triiodothyronine (T3), and only genistein acts as an inhibitor of type 1 deiodinase (Dio1) in vitro.
Recent studies suggest that genistein shows a good profile of safety on the thyroid, although definitive conclusions have not been reached.
As a type of phytoestrogen, genistein is classed as an endocrine disrupting chemical due to its estrogenic activity in vitro and in vivo. Consequently, excessive consumption of soy products has been linked to disruption of the reproductive organs, such as the uterus, breast, and testis.
On the other hand, isoflavones may also be considered endocrine disruptors with possible negative influences on the state of health in a certain part of the population or on the environment.
Due to their estrogenic effect, isoflavones present in soy such as genistein and daidzein may stimulate breast tumor growth and antagonize the antiproliferative action of tamoxifen. Supportive data are derived primarily from in vitro and animal studies; in vitro, low concentrations of these phytoestrogens have been found to promote DNA synthesis and reverse the inhibitory effect of tamoxifen on estrogen-dependent breast cancer cell proliferation.
In contrast, high concentrations of genistein greater than 10 μmol/L have been found to enhance tamoxifen effects by inhibiting breast cancer cell growth. It is not known if these high concentrations are normally achieved in humans. Plasma concentrations below 4 μmol/L have been observed in healthy volunteers given a soy diet for one month or large single doses of genistein. These concentrations are comparable to the low plasma concentrations associated with tumor stimulation reported in animals.
The herb-drug interaction with genistein usually involves enzyme-based and transporter-based interactions. Genistein shows various inhibitory and induction effects on the activities of cytochrome P450 and phase II enzymes, which can result in the detoxification of carcinogens or prevention of degradation for active compounds. These interactions have the potential to alter the pharmacokinetics of co-administered drugs metabolized by the same enzyme systems, though the magnitude of these effects in humans at nutritional doses requires further characterization.
Human dietary intervention trials and in vitro fecal metabolism studies with dietary plant polyphenols including isoflavones have revealed large inter-individual variations in absorption, metabolism, and excretion, which have been ascribed to differences in gut microbiota. This variability is clinically significant, as individuals who lack the gut microbiota necessary to convert isoflavone precursors to active aglycones, or who are unable to produce equol, may show markedly different clinical responses from those who can.
Health conditions that Genistein may help support.
Genistein, a soy isoflavone, is identified in multiple peer-reviewed reviews as a phytochemical possessing ALS activity. It acts via antioxidant and anti-apoptotic mechanisms, including upregulation of Bcl-2, suppression of intracellular ROS, and antioxidant enzyme modulation. Evidence is primarily preclinical from in vitro and animal model studies.
Genistein exhibits well-documented antioxidant activity through multiple mechanisms including direct ROS scavenging, upregulation of endogenous antioxidant enzymes, and increasing total antioxidant capacity. RCTs in T2DM patients demonstrated significant increases in total antioxidant capacity and reductions in malondialdehyde (MDA) with genistein supplementation.
Genistein has demonstrated protective effects on vascular endothelial function, systemic arterial compliance, and atherosclerosis in multiple clinical and preclinical studies. A 3-year placebo-controlled trial in postmenopausal women showed positive effects on cardiovascular risk factors. Meta-analysis confirms reductions in systolic and diastolic blood pressure alongside improved lipid markers. Mechanistically, genistein modulates NF-κB, reduces ox-LDL-induced injury, and suppresses the OX40/OX40L pathway implicated in atherosclerotic lesion development.
A systematic review and meta-analysis of RCTs found genistein supplementation significantly reduced both systolic and diastolic blood pressure. A 2025 meta-analysis of diverse population RCTs found SBP reduced by a mean of 8.32 mmHg and DBP by 3.57 mmHg. Results across studies are somewhat inconsistent, with a 2019 meta-analysis of 6 RCTs also reporting significant reductions.
Multiple RCTs and meta-analyses show genistein significantly reduces fasting blood glucose and HbA1c, particularly in postmenopausal women with type 2 diabetes. A 2017 meta-analysis of 7 RCTs found genistein reduced fasting glucose by approximately 6.35 mg/dL versus placebo. Preclinical evidence shows genistein supports pancreatic beta-cell function and glucose-stimulated insulin secretion.
Genistein, the principal soy isoflavone aglycone, inhibits osteoclast bone resorption and stimulates osteoblast differentiation via estrogen receptor-beta binding. A 3-year RCT in osteopenic postmenopausal women showed genistein significantly improved bone formation markers without adverse effects on breast or uterine tissue, and meta-analyses show modest positive BMD effects.
A 2016 meta-analysis of 8 RCTs confirmed that genistein significantly increases HDL-C and, specifically in women with metabolic syndrome, significantly decreases LDL-C, total cholesterol, and triglycerides. A 2025 meta-analysis of diverse RCTs further confirmed significant reductions in TC and LDL-C across broader populations.
Genistein demonstrates well-characterized anti-inflammatory activity by inhibiting NF-κB, prostaglandin synthesis, iNOS, and proinflammatory cytokines (TNF-α, IL-6, IL-1β). Both in vitro and animal studies confirm these effects, while clinical trials show reductions in CRP and other inflammatory markers. Evidence for anti-inflammatory pharmacological effects in humans is still developing.
Soy isoflavone interventions including genistein have improved certain cognitive functions in clinical studies, and genistein has shown neuroprotective activity in preclinical models. The Alzheimer's Research & Prevention Foundation's evidence review notes improvements in some cognitive domains, though no RCTs have tested genistein alone specifically for age-related cognitive decline.
Genistein is a soy isoflavone that acts as a selective estrogen receptor modulator (SERM) with preferential binding to ERβ, modulating estrogen-dependent tissues. Multiple RCTs have shown 54 mg/day genistein improves bone density and reduces menopausal vasomotor symptoms in postmenopausal women. It also inhibits aromatase and 17β-hydroxysteroid dehydrogenase in vitro, contributing to estrogen metabolism modulation.
Genistein addresses multiple hallmarks of aging including oxidative stress, chronic low-grade inflammation, hormonal decline, bone loss, skin collagen depletion, and metabolic dysregulation. Broad clinical trial evidence across these domains, predominantly in postmenopausal women, supports a multi-faceted role for genistein in healthy aging.
Genistein has documented cardioprotective effects including improved cardiac function, protection against ischemia-reperfusion injury, reduced cardiac toxicity, and favorable modulation of lipid profiles. A 2023 review and multiple clinical meta-analyses confirm these findings. Effects are attributed to anti-inflammatory, antioxidant, and estrogenic mechanisms.
Multiple RCTs and two independent meta-analyses confirm genistein supplementation significantly lowers plasma homocysteine levels. A meta-analysis of 8 RCTs (476 subjects) found a reduction of 0.58 µmol/L versus placebo. A later 2025 meta-analysis found a similar reduction of 0.74 µmol/L across 7 RCTs.
Genistein is the predominant soy isoflavone and has the strongest individual clinical evidence for menopausal hot flashes. A 2-year double-blind RCT (n=389) showed a 56.4% reduction in mean hot flush frequency after 12 months of 54 mg/day genistein without adverse endometrial effects. Evidence is among the strongest for any single phytoestrogen.
Genistein, a soy isoflavone, inhibits melanocyte proliferation and melanosome transfer to keratinocytes, reducing hyperpigmentation. Genistein content in soy extracts correlates strongly with antimelanogenic activity in cell-based studies. It is identified in systematic reviews as an active depigmenting compound.
RCTs demonstrate genistein improves insulin sensitivity indices including HOMA-IR and QUICKI in postmenopausal women with T2DM and in obese individuals with insulin resistance. A 2025 meta-analysis confirmed significant reductions in fasting insulin (MD −1.79) and HOMA-IR (MD −0.56) versus placebo.
Genistein is the primary active isoflavone in soy, acting as a phytoestrogen via preferential ERβ binding. Clinical RCTs show genistein-predominant preparations most effectively reduce menopausal hot flash frequency. A 2025 PMC review specifically identifies genistein and daidzein as natural phytoestrogens with potential HRT applications.
Genistein supplementation has been specifically studied in postmenopausal women with metabolic syndrome, where it produced significant improvements in LDL-C, total cholesterol, triglycerides, blood pressure, and insulin resistance markers. A meta-analysis confirmed these lipid-lowering effects are most pronounced in this subgroup. Multiple clinical trials also show reductions in fasting glucose and HOMA-IR in metabolic syndrome populations.
Genistein, the principal soy isoflavone, inhibits DNMT activity in a dose-dependent manner and induces gene-specific methylation changes. A 2025 PMC systematic review (PMC12554032) ranks genistein among the most studied food-derived DNMT modulators. Evidence includes preclinical models and some human observational data; dietary intake levels may be insufficient for DNMT effects.
Genistein is the predominant soy isoflavone with the strongest evidence for bone protection among the phytoestrogens. A randomized double-blind placebo-controlled study found genistein alone significantly reduced bone loss in early postmenopausal women compared to placebo. A meta-analysis identified genistein at 54 mg/day as having beneficial effects on BMD in postmenopausal women.
Genistein is the primary isoflavone in soy with documented insulin-sensitizing, anti-androgenic, and ovarian-protective properties in PCOS models. Clinical evidence shows it improves androgen levels, SHBG, and insulin resistance parameters in women with PCOS when used at physiological doses.
Genistein is the most bioactive soy and red clover isoflavone, binding ERβ preferentially and acting as a SERM. Clinical evidence supports reduction of hot flashes, night sweats, and improved bone mineral density in menopausal women. It is the most studied individual soy isoflavone for menopausal symptoms.
Genistein, the principal isoflavone in soy, inhibits prostate cancer cell growth, reduces PSA production, and blocks androgen receptor signaling. It has been examined in multiple RCTs for PSA modulation in prostate cancer patients and in men with elevated prostate cancer risk. Epidemiological data link high soy intake in Asian men to lower prostate cancer incidence.
Genistein has been studied both topically and via dietary intake for its effects on skin aging and wrinkle formation. Studies using human skin parameters, animal wrinkling models, and cell culture show that genistein reduces UVB-induced wrinkling, improves skin elasticity, and modulates collagen metabolism. A controlled multicenter study found isoflavone cream reduced facial wrinkles by 22%.
Genistein promotes increased collagen synthesis, stimulates fibroblast proliferation, increases hyaluronic acid and glycosaminoglycans, and reduces MMP-driven collagen degradation in the dermis. Clinical RCTs with topical genistein (4%) and dietary intake studies have demonstrated measurable improvements in skin elasticity and dermal collagen density.
Genistein protects skin against UVB-induced oxidative stress, inflammation, and wrinkling via antioxidant and anti-inflammatory mechanisms. Both dietary intake and topical application have been shown to suppress UVB-induced proinflammatory cytokines and reduce photoaging markers. Human, animal, and cell-culture data all support this relationship.
Genistein, the primary isoflavone aglycone in soy, has been shown in RCTs and meta-analyses to reduce triglycerides, particularly in postmenopausal women. It acts via ERβ and PPAR-alpha activation to reduce hepatic lipogenesis and increase fatty acid oxidation.
Genistein, a soy isoflavone phytoestrogen, has demonstrated antiproliferative effects on uterine leiomyoma cells in vitro and has been studied for its repressive effects on estradiol-induced uterine leiomyoma cell proliferation. It acts via estrogen receptor modulation relevant to uterine fibroid pathology.
Genistein is the primary isoflavone from soy with anti-androgenic properties including 5-alpha reductase type II inhibition and androgen receptor modulation relevant to androgenetic alopecia. It is the precursor to equol (in gut-competent individuals) and contributes to the hair-protective effects of soy isoflavone supplementation.
Body systems that Genistein may help support.
Go back